FtsZ as an Antibacterial Target: Status and Guidelines for Progressing This Avenue

Kusuma, KD; Payne, M; Ung, AT; Bottomley, AL; Harry, EJ

FtsZ as an Antibacterial Target: Status and Guidelines for Progressing This Avenue

Kusuma, KD Payne, M Ung, AT

Bottomley, AL

Harry, EJ

Permalink

Publication Type:: Journal Article
Citation:: ACS Infectious Diseases, 2019, 5 (8), pp. 1279 - 1294
Issue Date:: 2019-08-09

Closed Access

	Filename	Description	Size
	FtsZ as an Antibacterial Target Status and Guidelines for Progressing This Avenue.pdf	Published Version	6.05 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kusuma, KD	en_US
dc.contributor.author	Payne, M	en_US
dc.contributor.author	Ung, AT https://orcid.org/0000-0002-5665-0702	en_US
dc.contributor.author	Bottomley, AL https://orcid.org/0000-0003-0255-0869	en_US
dc.contributor.author	Harry, EJ https://orcid.org/0000-0003-0858-9473	en_US
dc.date.issued	2019-08-09	en_US
dc.identifier.citation	ACS Infectious Diseases, 2019, 5 (8), pp. 1279 - 1294	en_US
dc.identifier.uri	http://hdl.handle.net/10453/135356
dc.description.abstract	© 2019 American Chemical Society. The disturbing increase in the number of bacterial pathogens that are resistant to multiple, or sometimes all, current antibiotics highlights the desperate need to pursue the discovery and development of novel classes of antibacterials. The wealth of knowledge available about the bacterial cell division machinery has aided target-driven approaches to identify new inhibitor compounds. The main division target being pursued is the highly conserved and essential protein FtsZ. Despite very active research on FtsZ inhibitors for several years, this protein is not yet targeted by any commercial antibiotic. Here, we discuss the suitability of FtsZ as an antibacterial target for drug development and review progress achieved in this area. We use hindsight to highlight the gaps that have slowed progress in FtsZ inhibitor development and to suggest guidelines for concluding that FtsZ is actually the target of these molecules, a key missing link in several studies. In moving forward, a multidisciplinary, communicative, and collaborative process, with sharing of research expertise, is critical if we are to succeed.	en_US
dc.relation	http://purl.org/au-research/grants/arc/DP150102062
dc.relation.ispartof	ACS Infectious Diseases	en_US
dc.relation.isbasedon	10.1021/acsinfecdis.9b00055	en_US
dc.title	FtsZ as an Antibacterial Target: Status and Guidelines for Progressing This Avenue	en_US
dc.type	Journal Article
utslib.citation.volume	8	en_US
utslib.citation.volume	5	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
utslib.for	1108 Medical Microbiology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CCET - Centre for Clean Energy Technology
pubs.organisational-group	/University of Technology Sydney/Strength - ithree - Institute of Infection, Immunity and Innovation
utslib.copyright.status	closed_access
pubs.issue	8	en_US
pubs.publication-status	Published	en_US
pubs.volume	5	en_US

Abstract:

© 2019 American Chemical Society. The disturbing increase in the number of bacterial pathogens that are resistant to multiple, or sometimes all, current antibiotics highlights the desperate need to pursue the discovery and development of novel classes of antibacterials. The wealth of knowledge available about the bacterial cell division machinery has aided target-driven approaches to identify new inhibitor compounds. The main division target being pursued is the highly conserved and essential protein FtsZ. Despite very active research on FtsZ inhibitors for several years, this protein is not yet targeted by any commercial antibiotic. Here, we discuss the suitability of FtsZ as an antibacterial target for drug development and review progress achieved in this area. We use hindsight to highlight the gaps that have slowed progress in FtsZ inhibitor development and to suggest guidelines for concluding that FtsZ is actually the target of these molecules, a key missing link in several studies. In moving forward, a multidisciplinary, communicative, and collaborative process, with sharing of research expertise, is critical if we are to succeed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/135356